• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Enovis Corporation

    8/12/25 12:06:03 PM ET
    $ENOV
    Industrial Specialties
    Health Care
    Get the next $ENOV alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Enovis CORP

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    194014502

    (CUSIP Number)


    07/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    194014502


    1Names of Reporting Persons

    DAVENPORT & Co LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    VIRGINIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,730,225.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,756,145.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,756,270.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.83 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Enovis CORP
    (b)Address of issuer's principal executive offices:

    2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON, DELAWARE 19808
    Item 2. 
    (a)Name of person filing:

    DAVENPORT & Co LLC
    (b)Address or principal business office or, if none, residence:

    P O BOX 85678 RICHMOND, Virginia 23285-5678
    (c)Citizenship:

    DAVENPORT & Co LLC - VIRGINIA
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    194014502
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2,756,270
    (b)Percent of class:

    4.83  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    DAVENPORT & Co LLC - 2,730,225

     (ii) Shared power to vote or to direct the vote:

    DAVENPORT & Co LLC - 0

     (iii) Sole power to dispose or to direct the disposition of:

    DAVENPORT & Co LLC - 2,756,145

     (iv) Shared power to dispose or to direct the disposition of:

    DAVENPORT & Co LLC - 0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    DAVENPORT & Co LLC
     
    Signature:Alison Crowder
    Name/Title:CCO - Investment Advisory
    Date:08/12/2025
    Get the next $ENOV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ENOV

    DatePrice TargetRatingAnalyst
    1/6/2026$41.00Buy
    BTIG Research
    10/3/2024$62.00Mkt Outperform
    JMP Securities
    6/13/2024$53.00Neutral
    JP Morgan
    2/13/2024$72.00Overweight
    Stephens
    1/22/2024$75.00Buy
    UBS
    1/3/2024Outperform
    William Blair
    12/15/2023$62.00 → $70.00Buy
    Needham
    10/20/2023$75.00Buy
    ROTH MKM
    More analyst ratings

    $ENOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Enovis Corporation with a new price target

    BTIG Research initiated coverage of Enovis Corporation with a rating of Buy and set a new price target of $41.00

    1/6/26 8:55:57 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    JMP Securities initiated coverage on Enovis Corporation with a new price target

    JMP Securities initiated coverage of Enovis Corporation with a rating of Mkt Outperform and set a new price target of $62.00

    10/3/24 7:29:21 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    JP Morgan initiated coverage on Enovis Corporation with a new price target

    JP Morgan initiated coverage of Enovis Corporation with a rating of Neutral and set a new price target of $53.00

    6/13/24 7:06:52 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lalor Angela S was granted 845 shares, increasing direct ownership by 4% to 22,140 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    1/5/26 9:00:03 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Former EVP, Strategy & Bus Dev Pryor Daniel A sold $45,298 worth of shares (1,665 units at $27.21), decreasing direct ownership by 0.41% to 160,449 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    12/11/25 9:00:09 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Principal Accounting Officer Kleckner John bought $74,830 worth of shares (2,468 units at $30.32), increasing direct ownership by 25% to 12,302 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    11/28/25 4:30:09 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Conference

    Dallas, TX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, today announced that its management team will meet with investors at the 44th Annual J.P. Morgan Healthcare Conference with a presentation scheduled for Monday, January 12th, 2026, at 4:30 p.m. PST (7:30 p.m. EST). A link to the live audio webcast, as well as a copy of the accompanying presentation slides and a replay of this event, will be available on the company's website (www.enovis.com) at Events and Presentations.       About Enovis Enovis™ (NYSE:ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically di

    1/8/26 7:30:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Appoints Oliver Engert as Chief Administrative Officer

    Dallas, TX, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology company, has announced that Oliver Engert has been appointed Chief Administrative Officer, effective today. In this newly-created role, Oliver will be responsible for leading Enovis' strategy development, driving organizational efficiency and enhancing operational excellence to support the company in its next phase of profitable, capital-efficient growth. Damien McDonald, CEO of Enovis said, "Oliver's appointment comes at a very exciting time for Enovis. As we take steps to build on our strong foundation and unlock our future potential, his extensive knowledge, skills a

    1/5/26 4:15:00 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Announces Third Quarter 2025 Results

    Diversified growth platform delivers third-quarter sales growth of 9% on a reported basis, 7% organically Third-quarter Reconstructive sales grew 12% year-over-year on a reported basis, 9% organically October divestiture of Diabetic Footcare business unit from P&R for total proceeds of up to $60 million Raising full-year 2025 adjusted EBITDA and adjusted EPS guidance Dallas, TX, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended October 3, 2025. The Company will host an investor conference call and live webcast to discus

    11/6/25 6:01:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    SEC Filings

    View All

    Enovis Corporation filed SEC Form 8-K: Leadership Update

    8-K - Enovis CORP (0001420800) (Filer)

    12/15/25 4:05:35 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Enovis CORP (0001420800) (Filer)

    12/10/25 6:30:37 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Corporation filed SEC Form 8-K: Leadership Update

    8-K - Enovis CORP (0001420800) (Filer)

    11/14/25 4:05:37 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Accounting Officer Kleckner John bought $74,830 worth of shares (2,468 units at $30.32), increasing direct ownership by 25% to 12,302 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    11/28/25 4:30:09 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Chief Executive Officer Mcdonald Damien bought $199,973 worth of shares (6,457 units at $30.97), increasing direct ownership by 7% to 102,753 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    9/11/25 5:59:16 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SVP and Chief Legal Officer Tandy Bradley J bought $100,512 worth of shares (3,200 units at $31.41), increasing direct ownership by 8% to 43,515 units (SEC Form 4)

    4 - Enovis CORP (0001420800) (Issuer)

    8/25/25 6:30:04 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Leadership Updates

    Live Leadership Updates

    View All

    Enovis Appoints Oliver Engert as Chief Administrative Officer

    Dallas, TX, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven medical technology company, has announced that Oliver Engert has been appointed Chief Administrative Officer, effective today. In this newly-created role, Oliver will be responsible for leading Enovis' strategy development, driving organizational efficiency and enhancing operational excellence to support the company in its next phase of profitable, capital-efficient growth. Damien McDonald, CEO of Enovis said, "Oliver's appointment comes at a very exciting time for Enovis. As we take steps to build on our strong foundation and unlock our future potential, his extensive knowledge, skills a

    1/5/26 4:15:00 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Announces Appointment of Damien McDonald as Chief Executive Officer

    Damien McDonald appointed CEO, effective as of May 12, 2025Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "The Company") (NYSE:ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company's 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at th

    4/2/25 6:30:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Maplebear Set to Join S&P MidCap 400; Enovis to Join S&P SmallCap 600

    NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Maplebear Inc. (NASD: CART) will replace Enovis Corp. (NYSE:ENOV) in the S&P MidCap 400, and Enovis will replace Arch Resources Inc. (NYSE:ARCH) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 14. S&P SmallCap 600 constituent CONSOL Energy Inc. (NYSE:CEIX) is acquiring Arch Resources in a deal expected to be completed soon, pending final closing conditions. Following completion of the merger, CONSOL Energy will be renamed Core Natural Resources Inc., and its ticker will change to CNR. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index

    1/7/25 6:19:00 PM ET
    $ARCH
    $CART
    $CEIX
    Coal Mining
    Energy
    Real Estate
    Industrial Specialties

    $ENOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Enovis Corporation

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    11/14/24 1:28:31 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    4/5/24 12:21:51 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

    SC 13G/A - Enovis CORP (0001420800) (Subject)

    2/14/24 10:04:36 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    $ENOV
    Financials

    Live finance-specific insights

    View All

    Enovis Announces Third Quarter 2025 Results

    Diversified growth platform delivers third-quarter sales growth of 9% on a reported basis, 7% organically Third-quarter Reconstructive sales grew 12% year-over-year on a reported basis, 9% organically October divestiture of Diabetic Footcare business unit from P&R for total proceeds of up to $60 million Raising full-year 2025 adjusted EBITDA and adjusted EPS guidance Dallas, TX, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the third quarter ended October 3, 2025. The Company will host an investor conference call and live webcast to discus

    11/6/25 6:01:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis announces webcast and conference call for Third Quarter 2025 Results and participation in upcoming investor conferences

    Dallas, TX, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, announced today it will host an investor conference call and live webcast to discuss its third quarter 2025 financial results on Thursday, November 6th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, will be made available on the "Investors" section of Enovis' website at www.enovis.com. Additionally, the company also announced it will participate in the following investor conferences: UBS Global Healthcare Conference: Damien McD

    10/24/25 4:11:14 PM ET
    $ENOV
    Industrial Specialties
    Health Care

    Enovis Announces Second Quarter 2025 Results

    Continued commercial momentum with second-quarter sales growth of 7% on a reported basisSecond-quarter Reconstructive sales grew 11% year-over-year on a reported basis  Wilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Second Quarter 2025 Financial Results Enovis' second-quarter net sales of $565 million grew 7% on a reported basis and 5% on an organic basis from the same quarter

    8/7/25 6:00:00 AM ET
    $ENOV
    Industrial Specialties
    Health Care